Studying Cognition in SPG4

N/ACompletedNCT03104088

University Hospital Tuebingen50 enrolled

Overview

Comparing the cognitive levels of patients with SPG4 mutations to healthy controls.

Comparing the cognitive levels of patients with SPG4 mutations to healthy controls by using the CANTAB® and MoCA.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cognitive Impairment Hereditary Spastic Paraplegia

Interventions

CANTABDIAGNOSTIC_TEST

CANTAB Cognitive Assessment (tablet based cognitive testing from CAMCOG)

MOCADIAGNOSTIC_TEST

Montreal cognitive assessment (MOCA) in German

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with SPG4 with known SPAST-Mutation (patient group) or healthy control * Age 18 to 70 years * Written, informed consent Exclusion Criteria: * Lack of ability for a written, informed consent * Presence of gait disorder or other neurological condition (for healthy controls)

Locations (1)

University Hospital Tübingen, Center for Neurology

Tübingen, Germany

Outcomes

Primary Outcomes

Identifying cognitive affected domains by using CANTAB

Number of SPG4 patients with affections in the examined cognitive domains by using CANTAB

Time frame: day 1

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.